Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Phase 1 Study of the Pharmacology of BTI320 Before High-Glycemic Meals.

Luke DR, Lee KKY, Rausch CW, Cheng C.

Clin Pharmacol Drug Dev. 2019 Apr;8(3):395-403. doi: 10.1002/cpdd.583. Epub 2018 Jun 5.

2.

Clinical Pharmacokinetics of Sulfobutylether-β-Cyclodextrin in Patients With Varying Degrees of Renal Impairment.

Hoover RK, Alcorn H Jr, Lawrence L, Paulson SK, Quintas M, Luke DR, Cammarata SK.

J Clin Pharmacol. 2018 Jun;58(6):814-822. doi: 10.1002/jcph.1077. Epub 2018 Mar 26.

3.

Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment.

Hoover R, Marbury TC, Preston RA, Quintas M, Lawrence LE, Paulson SK, Luke DR, Cammarata SK.

J Clin Pharmacol. 2017 Mar;57(3):328-335. doi: 10.1002/jcph.817. Epub 2016 Oct 14.

4.

Telavancin hospital-acquired pneumonia trials: impact of Gram-negative infections and inadequate Gram-negative coverage on clinical efficacy and all-cause mortality.

Lacy MK, Stryjewski ME, Wang W, Hardin TC, Nogid B, Luke DR, Shorr AF, Corey GR, Barriere SL.

Clin Infect Dis. 2015 Sep 15;61 Suppl 2:S87-93. doi: 10.1093/cid/civ536.

PMID:
26316562
5.

Reconstruction of wave front and object for inline holography from a set of detection planes.

Hagemann J, Robisch AL, Luke DR, Homann C, Hohage T, Cloetens P, Suhonen H, Salditt T.

Opt Express. 2014 May 19;22(10):11552-69. doi: 10.1364/OE.22.011552.

PMID:
24921276
6.

Invasive Aspergillus infections in hospitalized patients with chronic lung disease.

Wessolossky M, Welch VL, Sen A, Babu TM, Luke DR.

Infect Drug Resist. 2013 May 27;6:33-9. doi: 10.2147/IDR.S43069. Print 2013.

7.

Discovery of Dap-3 polymyxin analogues for the treatment of multidrug-resistant Gram-negative nosocomial infections.

Magee TV, Brown MF, Starr JT, Ackley DC, Abramite JA, Aubrecht J, Butler A, Crandon JL, Dib-Hajj F, Flanagan ME, Granskog K, Hardink JR, Huband MD, Irvine R, Kuhn M, Leach KL, Li B, Lin J, Luke DR, MacVane SH, Miller AA, McCurdy S, McKim JM Jr, Nicolau DP, Nguyen TT, Noe MC, O'Donnell JP, Seibel SB, Shen Y, Stepan AF, Tomaras AP, Wilga PC, Zhang L, Xu J, Chen JM.

J Med Chem. 2013 Jun 27;56(12):5079-93. doi: 10.1021/jm400416u. Epub 2013 Jun 18.

PMID:
23735048
8.

Evaluation of intravenous voriconazole in patients with compromised renal function.

Lilly CM, Welch VL, Mayer T, Ranauro P, Meisner J, Luke DR.

BMC Infect Dis. 2013 Jan 16;13:14. doi: 10.1186/1471-2334-13-14.

9.

Pharmacokinetics of sulfobutylether-β-cyclodextrin (SBECD) in subjects on hemodialysis.

Luke DR, Wood ND, Tomaszewski KE, Damle B.

Nephrol Dial Transplant. 2012 Mar;27(3):1207-12. doi: 10.1093/ndt/gfr472. Epub 2011 Aug 24.

PMID:
21868395
10.

Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD).

Luke DR, Tomaszewski K, Damle B, Schlamm HT.

J Pharm Sci. 2010 Aug;99(8):3291-301. doi: 10.1002/jps.22109. Review.

PMID:
20213839
11.

Prospective observational study of patient-reported outcomes for azithromycin versus usual care in the treatment of bacterial acute exacerbation of chronic bronchitis.

Milstone A, Patsimas J, Farzan D, Castaldo R, Singh H, Feurer I, Harnett J, Luke DR; PROPeR Use Study Group.

Clin Ther. 2005 Jun;27(6):926-39.

PMID:
16117993
12.

Hybrid projection-reflection method for phase retrieval.

Bauschke HH, Combettes PL, Luke DR.

J Opt Soc Am A Opt Image Sci Vis. 2003 Jun;20(6):1025-34.

PMID:
12801170
13.

Phase retrieval, error reduction algorithm, and Fienup variants: a view from convex optimization.

Bauschke HH, Combettes PL, Luke DR.

J Opt Soc Am A Opt Image Sci Vis. 2002 Jul;19(7):1334-45.

PMID:
12095200
15.

Treatment of acute gynecologic infections with trovafloxacin. Trovafloxacin Surgical Group.

Roy S, Koltun W, Chatwani A, Martens MG, Dittrich R, Luke DR.

Am J Surg. 1998 Dec;176(6A Suppl):67S-73S.

PMID:
9935260
16.
17.

Double-blind comparison of single-dose alatrofloxacin and cefotetan as prophylaxis of infection following elective colorectal surgery. Trovafloxacin Surgical Group.

Milsom JW, Smith DL, Corman ML, Howerton RA, Yellin AE, Luke DR.

Am J Surg. 1998 Dec;176(6A Suppl):46S-52S.

PMID:
9935257
18.

Role of neutrophils and macrophages in experimental nephrosis of the rat.

Berens KL, Verani RR, Luke DR.

Ren Fail. 1998 Jan;20(1):53-63.

PMID:
9509560
19.

Pharmacokinetics of azithromycin after single- and multiple-doses in children.

Stevens RC, Reed MD, Shenep JL, Baker DK, Foulds G, Luke DR, Blumer JL, Rodman JH.

Pharmacotherapy. 1997 Sep-Oct;17(5):874-80.

PMID:
9324176
20.

Toleration of intravenous azithromycin.

Luke DR, Foulds G.

Ann Pharmacother. 1997 Sep;31(9):965-9.

PMID:
9296232
21.

Disposition of oral azithromycin in humans.

Luke DR, Foulds G.

Clin Pharmacol Ther. 1997 Jun;61(6):641-8.

PMID:
9209246
22.

Safety, toleration, and pharmacokinetics of intravenous azithromycin.

Luke DR, Foulds G, Cohen SF, Levy B.

Antimicrob Agents Chemother. 1996 Nov;40(11):2577-81.

23.

The absence of an effect of food on the bioavailability of azithromycin administered as tablets, sachet or suspension.

Foulds G, Luke DR, Teng R, Willavize SA, Friedman H, Curatolo WJ.

J Antimicrob Chemother. 1996 Jun;37 Suppl C:37-44.

PMID:
8818844
24.

Pharmacokinetics of azithromycin in pediatric patients with acute otitis media.

Nahata MC, Koranyi KI, Luke DR, Foulds G.

Antimicrob Agents Chemother. 1995 Aug;39(8):1875-7.

25.
26.

Phase I/II study of pentoxifylline with zidovudine on HIV-1 growth in AIDS patients.

Luke DR, McCreedy BJ, Sarnoski TP, Bookout JB, Johnston AM, Lell JE, Wiggan EB, Bell N, Limjuco RA, Guthrie KI, et al.

Int J Clin Pharmacol Ther Toxicol. 1993 Jul;31(7):343-50.

PMID:
8370633
27.

Influence of pentoxifylline on renal function in HIV-seropositive patients.

Luke DR, Sarnoski TP, Bell N, Dennis S.

Ren Fail. 1993;15(2):181-8.

PMID:
8469785
28.

Immunosuppressive effect of cyclosporine in the hyperlipidemic rat model.

Luke DR.

Biopharm Drug Dispos. 1992 Dec;13(9):635-45.

PMID:
1467451
29.

Failure of predicted creatinine clearance equations in HIV-seropositive patients.

Smith BL, Sarnoski TP, Dennis S, Luke DR.

Int J Clin Pharmacol Ther Toxicol. 1992 Oct;30(10):394-9.

PMID:
1446956
30.

Incidence of microalbuminuria in ambulatory patients with acquired immunodeficiency syndrome.

Luke DR, Sarnoski TP, Dennis S.

Clin Nephrol. 1992 Aug;38(2):69-74.

PMID:
1516282
31.

Bioavailability of labetalol in patients with end-stage renal disease.

Luke DR, Awni WM, Halstenson CE, Opsahl JA, Matzke GR.

Ther Drug Monit. 1992 Jun;14(3):203-8.

PMID:
1412606
32.

Pharmacokinetics of cyclosporine in bone marrow transplantation: longitudinal characterization of drug in lipoprotein fractions.

Luke DR, Brunner LJ, Lopez-Berestein G, Yau JC.

J Pharm Sci. 1992 Mar;81(3):208-11.

PMID:
1640354
33.

Effects of suprofen on the isolated perfused rat kidney.

Luke DR, Berens KL.

Ren Fail. 1992;14(2):187-92.

PMID:
1636026
34.

Role of vascular congestion in cisplatin-induced acute renal failure in the rat.

Luke DR, Vadiei K, Lopez-Berestein G.

Nephrol Dial Transplant. 1992;7(1):1-7.

PMID:
1316576
35.

Tissue distribution and in vivo immunosuppressive activity of liposomal cyclosporine.

Vadiei K, Lopez-Berestein G, Perez-Soler R, Luke DR.

Drug Metab Dispos. 1991 Nov-Dec;19(6):1147-51.

PMID:
1687023
36.

Antifungal activity of HWA-138 and amphotericin B in experimental systemic candidiasis.

Wasan KM, Vadiei K, Luke DR, Keyhani A, White RA, McQueen TJ, Mehta R, Lopez-Berestein G.

Antimicrob Agents Chemother. 1991 Oct;35(10):2046-8.

37.

Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys.

Hakimi J, Chizzonite R, Luke DR, Familletti PC, Bailon P, Kondas JA, Pilson RS, Lin P, Weber DV, Spence C, et al.

J Immunol. 1991 Aug 15;147(4):1352-9.

PMID:
1869828
38.

Reassessment of dapsone as a marker of acetylator phenotypes.

Wiggan EB, Dennis S, Reele SB, Luke DR.

Int J Clin Pharmacol Ther Toxicol. 1991 Jul;29(7):262-8.

PMID:
1889912
39.

Influence of pentoxifylline and related analogues in endotoxemic renal failure.

Berens KL, Langston JD, Wasan KM, Luke DR.

Circ Shock. 1991 Jul;34(3):344-8.

PMID:
1884436
40.

Effects of the immune system on cyclosporine absorption.

Luke DR.

Xenobiotica. 1991 Jun;21(6):817-24.

PMID:
1949911
41.

Benefit of vascular decongestion in glycerol-induced acute renal failure.

Luke DR, Berens KL, Verani RR.

Ren Fail. 1991;13(2-3):61-9.

PMID:
1957044
42.

Attenuation of amphotericin-B nephrotoxicity in the candidiasis rat model.

Luke DR, Wasan KM, Verani RR, Brunner LJ, Berens KL, Vadiei K, Lopez-Berestein G.

Nephron. 1991;59(1):139-44.

PMID:
1944727
43.

Therapeutic drug monitoring of cyclosporine-lipoprotein levels.

Yau JC, Brunner LJ, Lopez-Berestein G, LeMaistre CF, Luke DR.

Pharmacotherapy. 1991;11(4):291-5.

PMID:
1923909
44.

Cocaine Abuscreen in the emergency room.

Wiggan EB, Bell N, Luke DR.

J Toxicol Clin Toxicol. 1991;29(4):565-6. No abstract available.

PMID:
1749061
45.

Circadian variation in renal function of the obese rat.

Luke DR, Wasan KM, Vadiei K.

Ren Physiol Biochem. 1991;14(1-2):71-80.

PMID:
1706108
46.

Validity of creatinine clearance estimates in the assessment of renal function.

Luke DR, Halstenson CE, Opsahl JA, Matzke GR.

Clin Pharmacol Ther. 1990 Nov;48(5):503-8.

PMID:
2225710
47.

Evaluation of amphotericin B-cyclosporine interaction in the rat.

Langston JD, Wasan KM, Lopez-Berestein G, Verani RR, Luke DR.

Transplantation. 1990 Sep;50(3):506-10.

PMID:
2205957
48.

Enhancement of the treatment of experimental candidiasis with vascular decongestants.

Luke DR, Wasan KM, McQueen TJ, Lopez-Berestein G.

J Infect Dis. 1990 Jul;162(1):211-4.

PMID:
2355196
49.

Disposition and toxicity of amphotericin-B in the hyperlipidemic Zucker rat model.

Vadiei K, Lopez-Berestein G, Luke DR.

Int J Obes. 1990 Jun;14(6):465-72.

PMID:
2401582
50.

Pentoxifylline in the isolated perfused rat kidney.

Berens KL, Luke DR.

Transplantation. 1990 May;49(5):876-9.

PMID:
2336702

Supplemental Content

Support Center